Targeting the miR-32533/CREB5 axis: a promising immunomodulatory and therapeutic strategy for Alzheimer’s disease - Scorecard - MDSpire

Targeting the miR-32533/CREB5 axis: a promising immunomodulatory and therapeutic strategy for Alzheimer’s disease

  • By

  • Lizhen Li

  • Xiaolin Zhao

  • Li Zeng

  • Zixuan Li

  • Kaiyue Zhao

  • Zhongdi Cai

  • Rui Liu

  • May 4, 2026

  • 0 min

Share

Clinical Scorecard: Exploiting the miR-32533/CREB5 Pathway: An Innovative Approach for Immunomodulation and Treatment in Alzheimer's Disease

At a Glance

CategoryDetail
Condition
Key MechanismsInvolvement of miR-32533 in regulating CREB5, impacting Aβ metabolism, oxidative stress, and neuroinflammation, emphasizing the interplay between these factors.
Target Population
Care Setting

Key Highlights

  • AUC

Guideline-Based Recommendations

Diagnosis

    Management

    • S
    • u
    • g
    • g
    • e
    • s
    • t
    • s
    • p
    • e
    • c
    • i
    • f
    • i
    • c
    • t
    • h
    • e
    • r
    • a
    • p
    • e
    • u
    • t
    • i
    • c
    • s
    • t
    • r
    • a
    • t
    • e
    • g
    • i
    • e
    • s
    • o
    • r
    • e
    • x
    • a
    • m
    • p
    • l
    • e
    • s
    • o
    • f
    • i
    • n
    • t
    • e
    • r
    • v
    • e
    • n
    • t
    • i
    • o
    • n
    • s
    • t
    • a
    • r
    • g
    • e
    • t
    • i
    • n
    • g
    • t
    • h
    • e
    • m
    • i
    • R
    • -
    • 3
    • 2
    • 5
    • 3
    • 3
    • /
    • C
    • R
    • E
    • B
    • 5
    • p
    • a
    • t
    • h
    • w
    • a
    • y
    • .

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Individuals diagnosed with Alzheimer's Disease, particularly in early stages.

        Therapies targeting miR-32533 may provide neuroprotective effects and reduce neuroinflammation.

        Clinical Best Practices

        • multi-omics

        References

        Original Source(s)

        Targeting the miR-32533/CREB5 axis: a promising immunomodulatory and therapeutic strategy for Alzheimer’s disease

        • by Lizhen Li, Xiaolin Zhao, Li Zeng, Zixuan Li, Kaiyue Zhao, Zhongdi Cai, Rui Liu

        • May 4, 2026

        Related Content

        Disentangling on and off-target binding in flortaucipir PET: a voxel-to-voxel P-tau, ferric iron, and MAO-B histology-to-flortaucipir PET comparison

        The immune-endothelial axis in neurovascular pathophysiology: a framework for targeted interventions

        Opposing views or like-minded? International Working Group and Alzheimer’s Association criteria